PT1284740E - Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos - Google Patents
Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos Download PDFInfo
- Publication number
- PT1284740E PT1284740E PT01948222T PT01948222T PT1284740E PT 1284740 E PT1284740 E PT 1284740E PT 01948222 T PT01948222 T PT 01948222T PT 01948222 T PT01948222 T PT 01948222T PT 1284740 E PT1284740 E PT 1284740E
- Authority
- PT
- Portugal
- Prior art keywords
- autoimmune
- monosaccharide
- prophylactic
- infectious
- therapeutic treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20582000P | 2000-05-19 | 2000-05-19 | |
US28156701P | 2001-04-04 | 2001-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1284740E true PT1284740E (pt) | 2008-07-09 |
Family
ID=26900794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01948222T PT1284740E (pt) | 2000-05-19 | 2001-05-18 | Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos |
Country Status (21)
Country | Link |
---|---|
US (1) | US6800613B2 (pt) |
EP (2) | EP2000144A1 (pt) |
JP (1) | JP5004261B2 (pt) |
KR (1) | KR100829674B1 (pt) |
CN (1) | CN1606446A (pt) |
AT (1) | ATE395923T1 (pt) |
AU (3) | AU2001269695B2 (pt) |
BR (1) | BR0110975A (pt) |
CA (1) | CA2409221C (pt) |
CY (1) | CY1108211T1 (pt) |
DE (1) | DE60134134D1 (pt) |
DK (1) | DK1284740T3 (pt) |
ES (1) | ES2305086T3 (pt) |
HU (1) | HU230847B1 (pt) |
IL (3) | IL152935A0 (pt) |
MX (1) | MXPA02011486A (pt) |
NO (1) | NO331939B1 (pt) |
NZ (1) | NZ522755A (pt) |
PL (1) | PL206832B1 (pt) |
PT (1) | PT1284740E (pt) |
WO (1) | WO2001090129A2 (pt) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040006242A1 (en) * | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
US7915238B2 (en) | 1999-02-01 | 2011-03-29 | Eisai R & D Management Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
US20030105032A1 (en) * | 2000-05-19 | 2003-06-05 | Persing David H. | Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds |
WO2003022296A1 (en) * | 2001-09-07 | 2003-03-20 | The Trustees Of Boston University | Method and composition for treating immune complex associated disorders |
EP1302206A1 (en) * | 2001-10-11 | 2003-04-16 | Universitair Medisch Centrum Utrecht | Methods and means for the use of the adventitial toll-like receptor |
WO2003066065A1 (en) | 2002-02-04 | 2003-08-14 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
MXPA05000407A (es) | 2002-07-08 | 2005-04-19 | Corixa Corp | Procedimientos para la produccion de fosfato de aminoalquilglucosaminida e inmunoefectores de disacarido, e intermediarios para los mismos. |
RU2544850C2 (ru) | 2003-01-06 | 2015-03-20 | Корикса Корпорейшн | Некоторые аминоалкилглюкозаминидфосфатные производные и их применение |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
WO2005089122A2 (en) * | 2004-03-05 | 2005-09-29 | Mayo Foundation For Medical Education And Research | Animals with reduced body fat and increased bone density |
CN101107520A (zh) * | 2005-01-27 | 2008-01-16 | 希龙公司 | 特征鉴定靶向原发性囊性纤维化缺陷的药物效力的方法 |
KR101205064B1 (ko) | 2005-04-26 | 2012-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암 면역요법을 위한 조성물과 방법 |
GB0510463D0 (en) * | 2005-05-23 | 2005-06-29 | Britania Pharmaceuticals Ltd | Improvements in or relating to organic materials |
US7622128B2 (en) * | 2005-12-13 | 2009-11-24 | University Of Washington | Porphyromonas gingivalis 1435/1449 LPS as an immune modulator |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
PT2486938T (pt) | 2006-09-26 | 2018-06-12 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
US20090215710A1 (en) * | 2007-09-24 | 2009-08-27 | Reliance Life Sciences Pvt. Ltd. | Carbohydrate based toll-like receptor (tlr) antagonists |
EP2214692A2 (en) * | 2007-10-31 | 2010-08-11 | Centocor Ortho Biotech Inc. | Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions |
TWI494125B (zh) | 2009-06-05 | 2015-08-01 | Infectious Disease Res Inst | 合成的葡萄吡喃糖基脂質佐劑 |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
JP2013537892A (ja) * | 2010-09-22 | 2013-10-07 | ザ ユニバーシティー オブ メルボルン | 新規な免疫賦活法 |
GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
US9241988B2 (en) * | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
EA034351B1 (ru) | 2012-05-16 | 2020-01-30 | Иммьюн Дизайн Корп. | Трехкомпонентная вакцина против впг-2 и способы ее применения |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
WO2014141127A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response |
BR112015025709A2 (pt) | 2013-04-18 | 2017-07-18 | Immune Design Corp | monoterapia com gla para uso em tratamento de câncer |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CA2942234A1 (en) | 2014-03-12 | 2015-09-17 | Glaxosmithkline Biologicals S.A. | Liposomal compositions for mucosal delivery |
EP3116480A1 (en) | 2014-03-12 | 2017-01-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic liposomal formulation |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
WO2017013603A1 (en) | 2015-07-21 | 2017-01-26 | Glaxosmithkline Biologicals Sa | Adjuntive immunotherapy for the prevention or treatment of infectious disease |
TW201716084A (zh) | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
AU2016303387B2 (en) | 2015-08-06 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | TLR4 agonists and compositions thereof and their use in the treatment of cancer |
WO2017021912A1 (en) | 2015-08-06 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combined tlrs modulators with anti ox40 antibodies |
CR20180286A (es) | 2015-12-03 | 2018-07-16 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos de purina cíclicos como moduladores de sting |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
EP3440076B1 (en) | 2016-04-07 | 2022-06-01 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
WO2017191545A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
BR112019011365A2 (pt) | 2016-12-01 | 2019-10-22 | Glaxosmithkline Ip Dev Ltd | métodos para tratar câncer |
WO2018204302A1 (en) | 2017-05-01 | 2018-11-08 | Vanderbilt University | Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
JP2020536106A (ja) | 2017-10-05 | 2020-12-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Hivの処置に有用なインターフェロン遺伝子の刺激物質(sting)の調節物質 |
WO2019069270A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | GENERATOR STIMULATOR MODULATORS (STING) INTERFERON |
IL276608B2 (en) | 2018-02-12 | 2024-04-01 | Inimmune Corp | TOLL-like receptor ligands |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
WO2020030571A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof |
WO2020030570A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
WO2020261097A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
CA3142501A1 (en) | 2019-06-26 | 2020-12-30 | Axelia Oncology Pty Ltd | Novel molecules |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
US20220273789A1 (en) | 2019-07-21 | 2022-09-01 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
US20210069321A1 (en) | 2019-09-09 | 2021-03-11 | Glaxosmithkline Biologicals Sa | Immunotherapeutic compositions |
EP4034562A2 (en) | 2019-09-27 | 2022-08-03 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins |
CN112999233B (zh) * | 2019-12-19 | 2023-10-20 | 中国医学科学院药物研究所 | 一类来源于赤芍的单萜苷类化合物及其制法和应用 |
WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
CN116457364A (zh) * | 2020-11-11 | 2023-07-18 | 第一三共株式会社 | 新型氨基烷基氨基葡糖苷4-磷酸酯衍生物 |
EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
CA3212345A1 (en) | 2021-03-02 | 2022-09-09 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
JP2024511831A (ja) | 2021-03-31 | 2024-03-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質およびそれらの組み合わせ |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
US4844894A (en) * | 1984-07-12 | 1989-07-04 | Ribi Immunochem Research Inc. | Method of inhibiting the onset of septicemia and endotoxemia |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
EP0324455A3 (en) * | 1988-01-15 | 1991-03-27 | Hans O. Ribi | Novel polymeric immunological adjuvants |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
AU660325B2 (en) * | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
US6764840B2 (en) * | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6355257B1 (en) | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) * | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6368604B1 (en) * | 1997-09-26 | 2002-04-09 | University Of Maryland Biotechnology Institute | Non-pyrogenic derivatives of lipid A |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
BR9912067A (pt) * | 1998-07-14 | 2001-04-10 | American Cyanamid Co | Composição liofilizada, composição de vacina composta e aquosa composta da composição liofilizada, composição de vacina, método de imunização de um vertebrado através de vacinação, método para a preparação de uma composição liofilizada e de uma suspensão coloidal aquosa |
US6013640A (en) | 1998-08-21 | 2000-01-11 | Ribi Immunochem Research, Inc. | Phosphoglycolipid and methods for its use |
US6261573B1 (en) * | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
AU762369B2 (en) * | 1998-11-03 | 2003-06-26 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | LPS with reduced toxicity from genetically modified gram negative bacteria |
EP1206190A1 (en) * | 1999-08-06 | 2002-05-22 | Corixa Corporation | Vaccines for the treatment of autoimmune disease |
WO2001034794A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Biologicals S.A. | Casb7434, an antigen over-expressed in colon cancer |
US6699846B2 (en) * | 2000-03-17 | 2004-03-02 | Corixa Corporation | Mono- and disaccharides for the treatment of nitric oxide related disorders |
-
2001
- 2001-05-18 DK DK01948222T patent/DK1284740T3/da active
- 2001-05-18 CA CA2409221A patent/CA2409221C/en not_active Expired - Lifetime
- 2001-05-18 EP EP08153476A patent/EP2000144A1/en not_active Withdrawn
- 2001-05-18 BR BR0110975-8A patent/BR0110975A/pt not_active IP Right Cessation
- 2001-05-18 EP EP01948222A patent/EP1284740B1/en not_active Expired - Lifetime
- 2001-05-18 AU AU2001269695A patent/AU2001269695B2/en not_active Expired
- 2001-05-18 US US09/861,466 patent/US6800613B2/en not_active Expired - Lifetime
- 2001-05-18 AU AU6969501A patent/AU6969501A/xx active Pending
- 2001-05-18 MX MXPA02011486A patent/MXPA02011486A/es active IP Right Grant
- 2001-05-18 NZ NZ522755A patent/NZ522755A/en not_active IP Right Cessation
- 2001-05-18 KR KR1020027015626A patent/KR100829674B1/ko active IP Right Grant
- 2001-05-18 WO PCT/US2001/016327 patent/WO2001090129A2/en active Application Filing
- 2001-05-18 JP JP2001586316A patent/JP5004261B2/ja not_active Expired - Lifetime
- 2001-05-18 PL PL365169A patent/PL206832B1/pl not_active IP Right Cessation
- 2001-05-18 AT AT01948222T patent/ATE395923T1/de active
- 2001-05-18 IL IL15293501A patent/IL152935A0/xx unknown
- 2001-05-18 HU HU0301815A patent/HU230847B1/hu unknown
- 2001-05-18 DE DE60134134T patent/DE60134134D1/de not_active Expired - Lifetime
- 2001-05-18 ES ES01948222T patent/ES2305086T3/es not_active Expired - Lifetime
- 2001-05-18 CN CNA018114881A patent/CN1606446A/zh active Pending
- 2001-05-18 PT PT01948222T patent/PT1284740E/pt unknown
-
2002
- 2002-11-19 NO NO20025543A patent/NO331939B1/no not_active IP Right Cessation
- 2002-11-19 IL IL152935A patent/IL152935A/en unknown
-
2007
- 2007-05-11 AU AU2007202117A patent/AU2007202117B2/en not_active Expired
- 2007-10-08 IL IL186495A patent/IL186495A/en active IP Right Grant
-
2008
- 2008-07-24 CY CY20081100772T patent/CY1108211T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1284740E (pt) | Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos | |
MXPA02001911A (es) | Anticuerpos ctla-4 humanos y sus usos. | |
AU7574601A (en) | Tissue implant | |
EP0758904A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLOMERULONEPHRITIS AND OTHER IGNITIONS | |
AU2001280702A1 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
UA81676C2 (ru) | Композиция для лечения инфекций у крупного рогатого скота и свиней | |
HK1128679A1 (en) | 1,2-diphenylethene derivatives for treatment of immune diseases 12- | |
AP9801346A0 (en) | Xanthone analogs for the treatment of infectious diseases | |
DE69530844D1 (de) | Verfahren und substanzen gegen protozoen | |
MXPA03003741A (es) | Metodos y composiciones para el tratamiento de enfermedades oftalmicas. | |
DE69631381T2 (de) | Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen | |
IT1260149B (it) | Metodo per la preparazione e purificazione di miscele di fosfolipidi prive di contaminanti da virus non convenzionali | |
PT874843E (pt) | 4-(1h-benzimidazol-2-il)¬1,4|diazepinos substituidos uteis para o tratamento de doencas alergicas | |
AU2979899A (en) | Treatment of viral disease in swine | |
BR0113646A (pt) | Tratamento de distúrbios inflamatórios | |
DE60129552D1 (de) | E-selectin zur behandlung oder vorbeugung von schlaganfall | |
IL143279A0 (en) | Novel therapeutic application of low molecular weight heparin | |
WO2003060467A3 (en) | Method for analyzing effects of medical agents | |
NO984198L (no) | FremgangsmÕte for behandling av aggresjon | |
HUP0002639A2 (hu) | Eljárás a vastagbél bakteriális fertőzéséből eredő betegségek kezelésére | |
UA25749A (uk) | Спосіб хірургічhого лікуваhhя виразкової хвороби шлуhка | |
AU1278700A (en) | Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline | |
AU2002303988A1 (en) | Methods of treating alzheimer's disease | |
UA8295A (uk) | Спосіб відновлення функції спинного мозку | |
UA40177A (uk) | Спосіб лікування розладів гемодинаміки при інфекційно-токсичному шоці у дітей з інфекційними захворюваннями |